Evidence map›Paper›PMID 40740771›Full record

ArticleFrontiers in immunology2025

Identification of a stromal immunosuppressive barrier orchestrated by SPP1

Guichuang Ma, Xiaohan Liu, Qinrui Jiang, Shaowei Li, Qijing Wu, Bishan Liang, Fei Sun, Chunhui Gu, Wangjun Liao, Zhihua Zhang and 2 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. SPP1Frontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Guichuang Ma *Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Xiaohan Liu *Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Qinrui Jiang *Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Shaowei LiDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Qijing WuDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Bishan LiangDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Fei SunDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Chunhui GuDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Wangjun LiaoDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Zhihua ZhangDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Min ShiDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Qiong HuangDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The heterogeneity of immune cells is a critical manifestation of gastric cancer (GC) heterogeneity and significantly contributes to immune therapy resistance. Although previous studies have focused on the roles of specific myeloid cells and exhausted CD8 Methods: This study integrated multiple GC single-cell RNA sequencing, spatial transcriptomics, bulk-RNA sequencing, and single-cell immunotherapy datasets of our cohort (NFHGC Cohort). Methods such as single-cell subpopulation identification, transcriptomic analysis, spatial colocalization, cell communication network analysis and tissue immunofluorescence of gastric cancer were employed to investigate immune cell interactions and their molecular mechanisms in immune resistance. Results: By leveraging a comprehensive approach that integrates single-cell RNA sequencing, spatial transcriptomics, and bulk RNA-seq profiles, we identified 20 immune subsets with potential prognostic and therapeutic implications. Our findings suggest a stromal immunosuppressive network orchestrated by Macro_SPP1/C1QC macrophages and CD8_Tex_C1 T cells, which may form a barrier impeding antitumor immunity. Macrophage-derived MIF signaling appears to drive immunosuppression via the MIF-CD74/CXCR4/CD44 axis. Based on these observations, we developed a preliminary TME classification system using a gene signature derived from barrier-associated immune cell markers and unsupervised clustering. Conclusions: Our study identified a potential stromal immunosuppressive barrier in gastric cancer, driven by Macro_SPP1/C1QC macrophages and CD8_Tex_C1 T cells, which may contribute to immune dysfunction and therapy resistance. Molecular subtyping based on this barrier's presence could inform personalized immune therapy strategies.

Indexed as

CD8-Positive T-LymphocytesMacrophagesOsteopontinStomach NeoplasmsTumor EscapeDrug Resistance, NeoplasmHumansImmunotherapyLymphocytes, Tumor-InfiltratingSingle-Cell AnalysisTumor MicroenvironmentOsteopontincellular interaction networkexhausted CD8 + T cellsgastric cancerimmune microenvironmentimmunotherapy resistancemacrophages

Identifiers

PMID40740771
PMCPMC12307293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.